CoRegen is a biotechnology company developing regenerative therapies utilizing stem cell technology to promote tissue repair and regeneration. The company targets chronic injuries and degenerative diseases by providing precise treatments that enhance the body's natural healing processes.
Funding
$31.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often suffer from toxicity, inflammation, and off-target effects, limiting their effectiveness and impacting patients' quality of life. Existing treatments may also fail to fully eradicate cancer cells, leading to recurrence and the need for additional interventions.
Solution
CoRegen is developing a novel cancer therapy based on engineered T regulatory (Treg) cells designed to selectively target and eliminate cancer cells without harming healthy tissues. The approach involves modifying a single gene within Treg cells to enhance their ability to recognize and destroy cancer cells while avoiding the toxicity and inflammation associated with traditional treatments. By harnessing the power of the immune system, CoRegen aims to provide a more effective and less invasive treatment option that can eradicate cancer and prevent its recurrence. Preclinical studies have demonstrated the potential of this therapy to eliminate tumors in various aggressive cancer models with no observed toxicity. The company is advancing towards clinical trials with a focus on delivering accessible outpatient therapies.
Target Audience
The primary target audience includes patients with various types of cancer who are seeking more effective and less toxic treatment options, as well as oncologists and medical professionals involved in cancer care.
Features
- Engineered Treg cells that selectively target and destroy cancer cells
- Modification of a single gene to enhance Treg cell function
- Demonstrated eradication of tumors in preclinical mouse models
- Absence of toxicity, inflammation, or off-target effects in preclinical studies
- Potential for outpatient treatment administration
- Strong patent portfolio protecting the therapeutic approach